RXi Pharmaceuticals

RXi Pharmaceuticals, a clinical-stage drug company based in Marlborough, announced positive results from a clinical trial of its lead drug candidate, RXI-109.

RXi Pharmaceuticals Corp., a Marlborough clinical-stage company, has entered into a research collaboration with a German biotechnology company, Medigene.

Marlborough drugmaker RXI Pharmaceuticals Corp. on Friday announced a collaborative research agreement with the Center for Cancer Immune Therapy at Herlev Hospital in Denmark to evaluate the company's cancer treatment drugs.

RXi Pharmaceuticals in Marlborough has completed enrollment in a second phase of a clinical trial of an ointment meant to treat cutaneous warts.

RXi Pharmaceuticals reported a first quarter loss of $5.5 million, as the company dealt with increasing research and development costs following a January acquisition.

Marlborough drugmaker RXi Pharmaceuticals Corp. has completed its purchase of Cambridge cancer treatment company MirImmune Inc.

Marlborough drugmaker RXi Pharmaceuticals Corp. announced Thursday it has completed a $11.5-million public offering of its stock.

Clinical-stage drug company RXi Pharmaceuticals Corp. reported on Thursday it has kept its ongoing cash burn in line with projections while moving development programs forward and closing in on a recently announced acquisition.

Marlborough's RXi Pharmaceuticals Corporation has entered into an exclusive agreement to purchase Boston-based MirImmune Inc. and announced plans to raise funds for the purchase.

Marlborough's RXi Pharmaceuticals reported a steady year-over-year $2.2 million in losses as the clinical-stage therapeutics company continues to push forward on human trials of scarring treatments.